Structure Therapeutics reported new Phase 2 ACCESS II trial data showing that its investigational oral GLP-1 receptor agonist aleniglipron achieved 16.3% placebo-adjusted weight loss at 44 weeks in adults with obesity or overweight with comorbidities
Additionally, they reduce the production of glucagon, a hormone that raises blood sugar levels, and slow down the emptying of the stomach, leading to increased feelings of fullness and reduced appetite
Revisa el empaque por errores, sellos rotos o faltas ortogrficas
The average BMI before starting treatment was 34.7 kg/m 2 (Ozempic), 35.6 kg/m 2 (Wegovy) and 36.2 kg/m 2 (Mounjaro)
The building blocks: foods to prioritize for weight-loss success Power up on lean protein
Remember: It's not just about quantityit's about purposeful, measured research